Government Owned Invention Available for License: Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy
Notice
Health and Human Services Department, National Institutes of Health
Notice
July 16, 2026
2026-14346
📄 Summary
The National Cancer Institute (NCI) seeks capable licensees interested in commercializing T cell receptor (TCR)-engineered T cells expressing murine/human hybrid receptors.
